ARTBIO was founded by Roy Larsen, PhD inventor of the technology behind the breakthrough radiotherapeutic cancer drug, Xofigo. Occam placed Emanuele Ostuni, PhD the former head of Novartis Oncology's cell and gene therapy unit in Europe, as CEO.
The global start-up with offices in Oslo, London, Basel, and Boston just emerged from stealth with a robust pipeline and $23M from an international syndicate of investors, including F-Prime Capital and Omega Funds.
ARTBIO's board includes Ted Love, CEO of Global Blood Therapeutics until its $5.4B acquisition by Pfizer, and Susanne Schaffert, former President of Novartis Oncology. ARTBIO's lead asset in prostate cancer entered the clinic and will be developed quickly alongside other internal pipeline programs.
About Occam Global
Occam Global is an executive recruiting and leadership advisory firm with specialties across technological fields including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.